Development and Preclinical Evaluation of a Zirconium-89-Labeled Immunoconjugate for Positron Emission Tomography Imaging of Leukemia Inhibitory Factor in Glioblastoma.

ABSTRACT: Leukemia Inhibitory Factor (LIF) is a pleiotropic cytokine secreted by tumor cells to evade immune detection, contributing to tumor progression and resistance to therapy. Targeting LIF has emerged as a promising strategy, with anti-LIF therapies in clinical trials across a variety of cancers. Glioblastoma, a highly aggressive LIF-secreting brain tumor, is a critical target for these emerging therapies. This study aimed to develop an anti-LIF immunoPET agent for monitoring LIF expression in vivo, improving detection and targeted treatment strategies for glioblastoma. An anti-LIF antibody was conjugated to p-SCN-Bz-DFO and radiolabeled with positron-emitting zirconium-89 (⁸⁹Zr). Target binding properties and stability of the radioimmunoconjugate were assessed by ELISA and s

SUBMITTER: Betancourt Fernandez E 

PROVIDER: S-EPMC12624482 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature